8 0 treatment 0 20 40 60 80 100 120 Glaucoma is the leading cause of irreversible blindness worldwide with no approved neuroprotective treatments 1. Allison K et al. Cureus . 2020 Nov 24;12(11):e11686. 2. Precision Business Insights. Accessed May 2025.. 3. Coyle S, et al. Biomolecules . 2021 Aug 19;11(8):1239. ~80M Worldwide prevalence of glaucoma 1 • U.S. represents largest single market 2 • Global market expected to grow due to aging population; valued at ~$9B in 2025 2 ~112M 2020 2040 (Projected) ~4M in US • Current therapies focus on lowering intraocular pressure (IOP) as it is the only modifiable risk factor • The NLRP3 inflammasome complex is a key driver of neuroinflammation that results in optic neuropathy 3 Glaucoma is a progressive optic neuropathy driven by neuroinflammation There is an unmet need to develop new therapies that target the underlying neuroinflammation that drives optic neuropathy • Today’s small molecule delivery technologies (eye drops, orally, intravitreally) are limited in their ability to reach retinal and optic nerve targets Neuroinflammation Elevated IOP & Oxidative Stress D R I V E S R G C D A M A G E / D E A T H